Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | KRAS | P01116 | 6/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409669 | 0.93 | TGFBR1 (0.38) | LMNATP53MAPTTGFBR1RIPK1 | |
| SCHEMBL4407499 | 0.84 | MAPT (0.41) | MAPTKRASGPR119ESR2SCD5 | |
| SCHEMBL4418602 | 0.84 | RIPK1 (0.46) | RIPK1KRASESR2USP30 | |
| SCHEMBL4411026 | 0.84 | USP30 (0.40) | KRASESR2SCD5HRH3NR1H2 | |
| SCHEMBL4409890 | 0.83 | MTNR1A (0.44) | LMNATP53RIPK1HRH3MMP13 | |
| SCHEMBL4406512 | 0.81 | USP30 (0.49) | GPR119USP30 | |
| SCHEMBL4407107 | 0.81 | MAPK1 (0.44) | KRASGPR119ESR2NAMPTUSP30 | |
| SCHEMBL4410911 | 0.81 | GPR119 (0.39) | LMNATP53MAPTTGFBR1KRAS | |
| SCHEMBL4408978 | 0.80 | USP30 (0.39) | TP53MAPTTGFBR1KRASGPR119 | |
| SCHEMBL4406534 | 0.79 | ESR2 (0.40) | TP53RIPK1KRASGPR119ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | LMNA 3757/4885TP53 2722/4885MAPT 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.